Cell-Based Assay Market to Achieve $1.6 billion by 2017: companiesandmarkets.com

  • Cell-based assays proving first choice for drug compound screening using proteomics and genomics applications
  • Abundance of proteins with unknown functions will drive future growth
  • Other applications include: Diagnostics, genetics, toxicology, molecular biology, biochemistry and neuroscience

LONDON--(BUSINESS WIRE)-- The global market for cell-based assays is forecast to reach $1.6 billion by the 2017; growth driven by interest in drug discovery technology, toxicity screening, developments within the screening industry, and an increasing number of target molecules, according to a new report on companiesandmarkets.com.

Cell-Based Assays: A Global Strategic Business Report

http://www.companiesandmarkets.com/Market-Report/cell-based-assays-a-global-strategic-business-report-617862.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2

The US market for cell-based assays is the biggest, followed by Europe, which is expected to grow at a rate of 12% a year to 2017.

Pharmaceutical and biotech companies are trying to improve efficiencies and reduce costs associated with drug discovery. Many are turning to cell-based assays as an alternative to biochemical assays and in-vitro testing, as they can be used for multiple applications, such as identification and validation of targets, screening for efficacy and safety, and monitoring of cell-based activity – all with a guarantee of highly accurate data.

Another factor contributing to the rapid growth of the cell-based assay market includes the trend to use automated systems and high throughput screening (HTS) processes, which identify molecules with strong potential for successful drug development. Around half of all assays are used in primary HTS processes, which use cell lines which have been transformed or immortalized to enhance screening.

The cell-based assay market report contains profiles of 73 key companies, such as Thermo Fisher Scientific Inc; Agilent Technologies Inc; ProQinase GmbH; Invitrogen Corporation; Promega Corporation; Beckman Coulter Inc; BD Biosciences; BioVision Inc; PerkinElmer Inc; Hoffmann-La Roche Ltd; Cisbio Bioassays; Millipore Corporation; DiscoveRx Corporation; Caliper Life Sciences Inc, and GE Healthcare Life Sciences.

The 507 page report includes extensive analysis of the cell-based assay market, including historic and forecast data between 2003-2017, split by geographic markets - Europe, Japan, the US and Rest of World. The US market is reviewed in detail, specifically focusing on Assay Kits (including Cell Death-Associated Assays, Cell Growth-Associated Assays and Functional Assays), as well as Laboratory Automation. Overall analysis of market activities, trends, new technologies and other influencing market factors are also included.

Report Details:
http://www.companiesandmarkets.com/Market-Report/cell-based-assays-a-global-strategic-business-report-617862.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2



CONTACT:

Companies & Markets
Mike King
Press Office
[email protected]
London (UK): +44 (0) 203 086 8600

KEYWORDS:   United Kingdom  Europe

INDUSTRY KEYWORDS:   Stem Cells  Health  Biotechnology  Genetics  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.